Romain Boidot
Romain Boidot is an expert in Molecular biology at Centre Georges François Leclerc (France). Romain Boidot has authored 179 publications, the most recent in 2026, and is an investigator in 6 clinical trials. SLR score: 592 (community average: 125). How the SLR is computed.
LeadR Profile
Molecular biology
Subspecialties: Oncology - Hematology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 179
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer. PMID 42729982 — cells, genes, breast neoplasms, pharmaceutical preparations, neoplasms, phenotype, drug therapy, polyamines, breast, anthracyclines, therapeutics, chemotherapy | Cancer Drug Resist | 2026 | 0 |
| Age-related distribution of homologous recombination deficiency in advanced ovarian carcinoma: a large real-world French cohort. PMID 42462286 — cells, research design, recombination, genetic, homologous recombination, ovary, neoplasms, aged, recombinational dna repair, ovarian neoplasms, prevalence, therapeutics | Int J Gynecol Cancer | 2026 | 0 |
| Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response. PMID 42454784 — cells, neoplasms, carcinoma, non-small-cell lung, diet, immunotherapy, therapeutics, inulin, gastrointestinal microbiome | Gut Microbes | 2026 | 0 |
| Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers. PMID 42343427 — cells, cetuximab, neoplasms, squamous cell carcinoma of head and neck, fibroblasts, head and neck neoplasms, therapeutics, medical oncology | J Exp Clin Cancer Res | 2026 | 0 |
| IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy. PMID 42331382 — cells, killer cells, natural, macrophages, neoplasms, immunotherapy, immunity, vascular endothelial growth factor receptor-2, therapeutics, colorectal neoplasms, interleukin-10, angiogenesis | J Immunother Cancer | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map